Phosphagenics signs agreement with CSL

Phosphagenics announced Friday that it has signed a research and option agreement with CSL to evaluate Phosphagenics’ TPM technology to deliver large proteins.

TPM technology is a non-invasive platform system for the delivery of a range of different molecules including insulin, morphine, retinoic acid, oxycodone, lidocaine and diclofenac.

Pursuant to the collaborative arrangement, Phosphagenics will develop new formulations containing its patented TPM delivery system in combination with a number of CSL’s protein-based formulations.

CSL will assess the formulations in a mouse model to establish efficiency of delivery after topical application.

Should the TPM formulations prove successful the collaboration will expand to optimise their effect, as well as testing their effect in higher order animals.

Under the terms of the agreement Phosphagenics will receive undisclosed option, milestone and royalty payments should CSL elect to pursue formulations that result from the collaboration.